Multifunctional porous silicon nanoparticles for cancer theranostics

Biomaterials

Volumn 48, Issue , 2015, Pages 108-118

  Wang, Chang Fang ^a   Sarparanta, Mirkka P ^a   Mäkilä, Ermei M ^a,b   Hyvönen, Maija L K ^a   Laakkonen, Pirjo M ^a   Salonen, Jarno J ^b   Hirvonen, Jouni T ^a   Airaksinen, Anu J ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer therapy; Porous silicon nanoparticles; Surface multifunctionalization; Targeting drug delivery; Theranostics

Indexed keywords

CONTROLLED DRUG DELIVERY; DIAGNOSIS; DISEASES; FLUORESCENCE; MAMMALS; NANOPARTICLES; NANOSYSTEMS; ONCOLOGY; PARTICLE BEAMS; SILICON COMPOUNDS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TARGETED DRUG DELIVERY; THERANOSTICS; TUMORS;

AZIDE-ALKYNE CYCLOADDITION; CANCER THERAPY; DIAGNOSTIC IMAGING; DRUG DISSOLUTION RATES; FLUORESCENT LABELING; MULTI-FUNCTIONALIZATION; SILICON NANOPARTICLES; TARGETING DRUG DELIVERIES;

POROUS SILICON;

FLUORESCENT DYE; INDIUM 111; NANOCARRIER; NANOPARTICLE; POROUS SILICON NANOPARTICLE; SILICON; SORAFENIB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER THERAPY; CLICK CHEMISTRY; CONTROLLED STUDY; CYCLOADDITION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; EX VIVO STUDY; HUMAN; HYDROPHOBICITY; IMMUNOFLUORESCENCE TEST; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE LEVEL; TUMOR GROWTH; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; NEOPLASMS; NUDE MOUSE; THERANOSTIC NANOMEDICINE; TUMOR CELL LINE;

ALEXA;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; HUMANS; MALE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; SILICON; THERANOSTIC NANOMEDICINE;

EID: 84924989957     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.01.008     Document Type: Article

References (50)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
2. Edwards B.K., Noone A.-M., Mariotto A.B., Simard E.P., Boscoe F.P., Henley S.J., et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014, 120:1290-1314.
3. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. JCell Biol 2010, 188:759-768.
4. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002, 2:83-90.
5. Ryu J.H., Lee S., Son S., Kim S.H., Leary J.F., Choi K., et al. Theranostic nanoparticles for future personalized medicine. JControl Release 2014, 190:477-484.
6. Bimbo L.M., Sarparanta M., Santos H.A., Airaksinen A.J., Mäkilä E., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
7. Hong H., Chen F., Zhang Y., Cai W. New radiotracers for imaging of vascular targets in angiogenesis-related diseases. Adv Drug Deliv Rev 2014, 76:2-20.
8. Cutler C.S., Hennkens H.M., Sisay N., Huclier-Markai S., Jurisson S.S. Radiometals for combined imaging and therapy. Chem Rev 2013, 113:858-883.
9. Xie J., Lee S., Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010, 62:1064-1079.
10. Couvreur P. Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev 2013, 65:21-23.
11. Bai F., Wang C., Lu Q., Zhao M., Ban F.Q., Yu D.H., et al. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer. Biomaterials 2013, 34:6163-6174.
12. Bigini P., Previdi S., Casarin E., Silvestri D., Violatto M.B., Facchin S., et al. Invivo fate of avidin-nucleic acid nanoassemblies as multifunctional diagnostic tools. ACS Nano 2014, 8:175-187.
13. Chen Q., Wang C., Cheng L., He W., Cheng Z., Liu Z. Protein modified upconversion nanoparticles for imaging-guided combined photothermal and photodynamic therapy. Biomaterials 2014, 35:2915-2923.
14. Li J., He Y., Sun W., Luo Y., Cai H., Pan Y., et al. Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials 2014, 35:3666-3677.
15. Zhang H., Liu D., Shahbazi M.A., Mäkilä E., Herranz-Blanco B., Salonen J., et al. Fabrication of a multifunctional nano-in-micro drug delivery platform by microfluidic templated encapsulation of porous silicon in polymer matrix. Adv Mater 2014, 26:4497-4503.
16. Kinnari P.J., Hyvonen M.L., Mäkilä E.M., Kaasalainen M.H., Rivinoja A., Salonen J.J., et al. Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy. Biomaterials 2013, 34:9134-9141.
17. Liu D., Zhang H., Herranz-Blanco B., Mäkilä E., Lehto V.P., Salonen J., et al. Microfluidic assembly of monodisperse multistage pH-responsive polymer/porous silicon composites for precisely controlled multi-drug delivery. Small 2014, 10:2029-2038.
18. Shahbazi M.A., Hamidi M., Mäkilä E.M., Zhang H., Almeida P.V., Kaasalainen M., et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013, 34:7776-7789.
19. Bimbo L.M., Denisova O.V., Mäkilä E., Kaasalainen M., De Brabander J.K., Hirvonen J., et al. Inhibition of influenza a virus infection invitro by saliphenylhalamide-loaded porous silicon nanoparticles. ACS Nano 2013, 7:6884-6893.
20. Bimbo L.M., Mäkilä E., Raula J., Laaksonen T., Laaksonen P., Strommer K., et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011, 32:9089-9099.
21. Liu D., Bimbo L.M., Mäkilä E., Villanova F., Kaasalainen M., Herranz-Blanco B., et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. JControl Release 2013, 170:268-278.
22. Sarparanta M.P., Bimbo L.M., Mäkilä E.M., Salonen J.J., Laaksonen P.H., Helariutta A.M., et al. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials 2012, 33:3353-3362.
23. Santos H.A., Riikonen J., Salonen J., Mäkilä E., Heikkilä T., Laaksonen T., et al. Invitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 2010, 6:2721-2731.
24. Rytkönen J., Miettinen R., Kaasalainen M., Lehto V.-P., Salonen J., Närvänen A. Functionalization of mesoporous silicon nanoparticles for targeting and bioimaging purposes. JNanomater 2012, 2012:896562.
25. Kaasalainen M., Mäkilä E., Riikonen J., Kovalainen M., Järvinen K., Herzig K.H., et al. Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations. Int J Pharm 2012, 431:230-236.
26. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Bjorkqvist M., Heikkilä T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. JControl Release 2005, 108:362-374.
27. Santos H.A., Bimbo L.M., Lehto V.P., Airaksinen A.J., Salonen J., Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol 2011, 8:228-249.
28. Jarvis K.L., Barnes T.J., Prestidge C.A. Surface chemical modification to control molecular interactions with porous silicon. JColloid Interface Sci 2011, 363:327-333.
29. Wang C.F., Mäkilä E.M., Kaasalainen M.H., Liu D., Sarparanta M.P., Airaksinen A.J., et al. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake. Biomaterials 2014, 35:1257-1266.
30. 18F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution invivo with positron emission tomography. Mol Pharmacol 2011, 8:1799-1806.
31. Liu X., Chen Y., Li H., Huang N., Jin Q., Ren K., et al. Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior. ACS Nano 2013, 7:6244-6257.
32. Lallana E., Sousa-Herves A., Fernandez-Trillo F., Riguera R., Fernandez-Megia E. Click chemistry for drug delivery nanosystems. Pharm Res 2012, 29:1-34.
33. Jewett J.C., Bertozzi C.R. Cu-free click cycloaddition reactions in chemical biology. Chem Soc Rev 2010, 39:1272-1279.
34. Sawoo S., Dutta P., Chakraborty A., Mukhopadhyay R., Bouloussa O., Sarkar A. Anew bio-active surface for protein immobilisation via copper-free 'click' between azido SAM and alkynyl Fischer carbene complex. Chem Commun 2008, 7:5957-5959.
35. Manova R.K., Pujari S.P., Weijers C.A., Zuilhof H., van Beek T.A. Copper-free click biofunctionalization of silicon nitride surfaces via strain-promoted alkyne-azide cycloaddition reactions. Langmuir 2012, 28:8651-8663.
36. Lee D.E., Na J.H., Lee S., Kang C.M., Kim H.N., Han S.J., et al. Facile method to radiolabel glycol chitosan nanoparticles with Cu via copper-free click chemistry for microPET imaging. Mol Pharmacol 2013, 10:2190-2198.
37. Al-Jamal K.T., Nunes A., Methven L., Ali-Boucetta H., Li S., Toma F.M., et al. Degree of chemical functionalization of carbon nanotubes determines tissue distribution and excretion profile. Angew Chem Int Ed Engl 2012, 51:6389-6393.
38. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
39. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
40. Han H.D., Byeon Y., Jeon H.N., Shin B.C. Enhanced localization of anticancer drug in tumor tissue using polyethylenimine-conjugated cationic liposomes. Nanoscale Res Lett 2014, 9:9-209.
41. Nichols J.W., Bae Y.H. EPR: evidence and fallacy. JControl Release 2014, 190C:451-464.
42. Lammers T., Peschke P., Kuhnlein R., Subr V., Ulbrich K., Huber P., et al. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia 2006, 8:788-795.
43. Kovalainen M., Mönkäre J., Kaasalainen M., Riikonen J., Lehto V.P., Salonen J., et al. Development of porous silicon nanocarriers for parenteral peptide delivery. Mol Pharmacol 2013, 10:353-359.
44. Huang S.F., Kim S.J., Lee A.T., Karashima T., Bucana C., Kedar D., et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 2002, 62:5720-5726.
45. Awada A., Hendlisz A., Gil T., Bartholomeus S., Mano M., de Valeriola D., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005, 92:1855-1861.
46. Ravandi F., Cortes J.E., Jones D., Faderl S., Garcia-Manero G., Konopleva M.Y., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. JClin Oncol 2010, 28:1856-1862.
47. Jain L., Woo S., Gardner E.R., Dahut W.L., Kohn E.C., Kummar S., et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol 2011, 72:294-305.
48. Boudou-Rouquette P., Narjoz C., Golmard J.L., Thomas-Schoemann A., Mir O., Taieb F., et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 2012, 7. e42875.
49. Botchkina G.I., Zuniga E.S., Rowehl R.H., Park R., Bhalla R., Bialkowska A.B., et al. Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. PLoS One 2013, 8. e69884.
50. Su S., Wang H., Liu X., Wu Y., Nie G. iRGD-coupled responsive fluorescent nanogel for targeted drug delivery. Biomaterials 2013, 34:3523-3533.